Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR PRESERVATIVE FREE vs TROMETHAMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.
Tromethamine is a proton acceptor that buffers hydrogen ions, correcting metabolic acidosis by increasing bicarbonate and base excess. It acts as a weak base with high buffering capacity.
FDA-approved: Treatment of ocular inflammation and pain following cataract surgery and corneal refractive surgery.,Off-label: Relief of seasonal allergic conjunctivitis symptoms, management of cystoid macular edema, and treatment of postoperative inflammation in other ocular procedures.
Metabolic acidosis associated with cardiac arrest,Correction of metabolic acidosis in acute respiratory acidosis,Metabolic acidosis in renal failure,Metabolic acidosis in diabetes mellitus
1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.
Intravenous: 1 M solution (3.6 g/30 m L) administered via central line; usual adult dose 300-500 mg/kg (0.27-0.45 g/kg) given over 1-2 hours; may be repeated based on blood gas monitoring.
Terminal elimination half-life is approximately 5-6 hours in adults, but can be prolonged in elderly patients (up to 8-9 hours) and in patients with renal impairment (up to 13-19 hours).
Terminal elimination half-life: 2–3 hours in adults with normal renal function. May be prolonged in renal impairment.
Ketorolac undergoes hepatic metabolism via hydroxylation and conjugation (glucuronidation) to inactive metabolites. It is primarily metabolized by CYP2D6 and CYP3A4 isoenzymes, with renal excretion of metabolites and unchanged drug.
Tromethamine is not metabolized; it is primarily excreted unchanged by the kidneys.
Primarily renal excretion of metabolites and unchanged drug; approximately 80% of a dose is excreted in urine as ketorolac and its hydroxy metabolites, with about 6% excreted in feces.
Renal excretion of unchanged drug: >95%. Negligible biliary or fecal elimination.
99% bound to plasma proteins, primarily albumin.
<10% bound to plasma proteins (albumin).
0.15-0.25 L/kg after oral administration; for ophthalmic use, systemic absorption is minimal, so Vd is not clinically meaningful.
0.3–0.4 L/kg; primarily distributes in extracellular fluid.
Ophthalmic administration: Systemic bioavailability is approximately 0.5-1% after ocular instillation due to low corneal penetration and rapid clearance; oral bioavailability is 100%.
Not available (administered intravenously only; oral bioavailability is negligible due to lack of absorption).
No dosage adjustment required for renal impairment. Drug is minimally absorbed systemically.
Contraindicated in anuria or severe renal impairment (GFR < 30 m L/min). Use with caution in renal insufficiency; monitor acid-base balance. No specific dose adjustment guidelines; avoid in renal failure.
No dosage adjustment required for hepatic impairment. Drug is minimally absorbed systemically.
No specific Child-Pugh based dose adjustments; use with caution in hepatic impairment as metabolism is minimal (primarily renal excretion). Monitor electrolytes and p H.
Children ≥3 years: 1 drop into affected eye(s) four times daily. Safety and efficacy in children <3 years not established.
Intravenous: 1 M solution; dose based on calculated base deficit: m L of 0.3 M THAM = body weight (kg) × base deficit (m Eq/L) × 1.1. Administer over 1-2 hours via central line. Maximum infusion rate: 5 m L/kg/hour.
No specific dosage adjustment required. Use same dose as adults; monitor for tolerability.
No specific dose adjustment; monitor renal function and avoid in geriatric patients with renal impairment due to decreased creatinine clearance. Use lower end of dosing range and monitor acid-base status frequently.
NSAIDs may increase the risk of serious cardiovascular events (e.g., myocardial infarction, stroke) and gastrointestinal events (e.g., bleeding, ulceration, perforation). However, due to low systemic absorption with ophthalmic use, this boxed warning is less clinically relevant but still applies.
There is no FDA black box warning for tromethamine.
Use with caution in patients with compromised ocular surface, history of herpes simplex keratitis, bleeding tendencies, or those on anticoagulants. Prolonged use may delay wound healing. Monitor for signs of corneal epithelial breakdown or infection.
Monitor blood p H, p CO2, and electrolytes (especially potassium) during infusion,Use with caution in patients with renal impairment due to risk of accumulation,May cause respiratory depression, especially in patients with impaired renal function,Avoid extravasation due to tissue necrosis,Not recommended for neonatal use due to risk of hyperosmolality
Hypersensitivity to ketorolac or any component of the formulation; patients with active ocular infection or advanced dry eye; history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs.
Anuria or uremia,Chronic respiratory acidosis,Hypoglycemia,Hyperkalemia,Hypocalcemia,Known hypersensitivity to tromethamine
No known food interactions. No dietary restrictions required.
No known food interactions. However, electrolyte imbalances (e.g., hypokalemia) may be affected by dietary potassium intake; maintain a balanced diet per clinician advice.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to 1.5-3 times the human exposure. However, because NSAIDs can cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester, use is contraindicated after 30 weeks gestation. In first and second trimesters, use only if potential benefit justifies potential fetal risk.
Tromethamine is a parenteral alkalinizing agent used in metabolic acidosis. Animal reproduction studies have not been conducted. It is not known whether tromethamine can cause fetal harm when administered to a pregnant woman. Use during pregnancy only if clearly needed. Risk cannot be ruled out.
Ketorolac is excreted in human milk following oral administration. After a single intramuscular dose of 10 mg, the milk-to-plasma (M/P) ratio was 0.037. Low levels are expected in breastmilk; however, due to potential adverse effects of NSAIDs on neonates, caution is advised. Use is generally avoided in nursing mothers, especially with premature infants or those with thrombocytopenia or renal impairment.
It is not known whether tromethamine is excreted in human milk. The M/P ratio is undetermined. Caution should be exercised when administered to a nursing woman.
No specific pharmacokinetic studies in pregnancy. Dosing should be at the lowest effective dose for the shortest duration. Avoid use after 30 weeks gestation. No adjustment for first or second trimester unless renal function changes.
No specific dosing adjustments are recommended for pregnancy. However, pharmacokinetic changes in pregnancy (increased plasma volume, altered renal function) may necessitate careful monitoring and titration based on clinical and laboratory response.
ACULAR (ketorolac tromethamine ophthalmic solution) is an NSAID for ocular use. Preservative-free formulation is indicated for single-use to avoid corneal toxicity. Apply with caution in patients with bleeding disorders or those on anticoagulants due to risk of ocular bleeding. Prolonged use may delay corneal healing. Monitor for signs of keratitis or conjunctival hyperemia.
Tromethamine (THAM) is an amino alcohol that acts as a proton acceptor, used to correct metabolic acidosis when sodium bicarbonate is contraindicated (e.g., hypernatremia, hypercapnia). It is preferred in patients with lactic acidosis or respiratory acidosis because it does not generate CO2. Monitor serum potassium closely as it can cause hypokalemia. Extravasation causes tissue necrosis; administer via central line if possible. Correct dosing is based on base deficit: m L of 0.3 M THAM = base deficit (m Eq/L) × weight (kg) × 1.1.
Use exactly as prescribed; do not touch the dropper tip to any surface to avoid contamination.,Each single-use vial is for one dose only; discard after use to prevent infection.,Remove contact lenses before instillation and wait 10 minutes before reinserting.,Do not drive or operate machinery if vision is blurry after application.,Report eye pain, increased redness, or vision changes to your doctor immediately.
This medication is used to treat acidosis (too much acid in the blood).,It is given intravenously (IV) by your healthcare provider.,Report any signs of IV site reaction: pain, redness, swelling, or blistering.,You may need frequent blood tests to monitor your acid-base balance and potassium levels.,Tell your doctor if you have kidney disease or low blood potassium before treatment.
No interactions on record
"Methotrimeprazine may reduce the gastrointestinal absorption of tromethamine, an alkalinizing agent, leading to decreased systemic exposure and potentially diminished therapeutic efficacy. This interaction is hypothesized to occur via altered gastric pH or motility, though direct evidence is limited. Patients may experience reduced effectiveness of tromethamine in managing acid-base disorders."
"Tromethamine, an alkalinizing agent used to correct metabolic acidosis, can increase gastric pH, which may reduce the absorption of weakly acidic drugs like estrone sulfate. This altered gastrointestinal environment can decrease estrone sulfate bioavailability, potentially compromising its systemic effects for hormone replacement therapy. Clinically, this may lead to reduced efficacy of estrone sulfate, requiring dose adjustments or alternative administration routes."
"Tromethamine, an alkalinizing agent, can increase urinary pH, which enhances the renal excretion of sotalol, a class III antiarrhythmic that is primarily eliminated unchanged by the kidneys. This interaction may lead to reduced serum sotalol concentrations, potentially decreasing its therapeutic efficacy and increasing the risk of arrhythmia recurrence, particularly in patients with renal impairment or those requiring precise antiarrhythmic control."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR PRESERVATIVE FREE vs TROMETHAMINE, answered by our medical review team.
ACULAR PRESERVATIVE FREE is a NSAID Ophthalmic that works by Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.. TROMETHAMINE is a Alkalinizing Agent (Buffer) that works by Tromethamine is a proton acceptor that buffers hydrogen ions, correcting metabolic acidosis by increasing bicarbonate and base excess. It acts as a weak base with high buffering capacity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR PRESERVATIVE FREE and TROMETHAMINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR PRESERVATIVE FREE is: 1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.. The standard adult dose of TROMETHAMINE is: Intravenous: 1 M solution (3.6 g/30 m L) administered via central line; usual adult dose 300-500 mg/kg (0.27-0.45 g/kg) given over 1-2 hours; may be repeated based on blood gas monitoring.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR PRESERVATIVE FREE and TROMETHAMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR PRESERVATIVE FREE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to. TROMETHAMINE is classified as Category C. Tromethamine is a parenteral alkalinizing agent used in metabolic acidosis. Animal reproduction studies have not been conducted. It is not known whether tromethamine can cause feta. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.